We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Sensor Technology Can Improve Accuracy of Prostate Cancer Diagnosis

By LabMedica International staff writers
Posted on 22 Jul 2015
A smart sensor chip that is able to pick up on subtle differences in glycoprotein molecules can improve the accuracy and efficiency of prostate cancer diagnosis.

Glycoprotein molecules, proteins that are covalently bound to one or more carbohydrate chains, perform a wide range of functions in cell surfaces, structural tissues and blood and because of their essential role in our immune response, they are useful clinical biomarkers for detecting prostate cancer and other diseases.

Chemists at the University of Birmingham (Edgbaston, UK) created a sensor chip with synthetic receptors along a two dimensional surface to identify specific, targeted glycoprotein molecules that are differentiated by their modified carbohydrate chains. More...
To engineer the sensor chip, the team developed a smart surface with nano-cavities that fit the particular target glycoprotein.

To create the nano-cavities, the sugar part of the prostate cancer glycoprotein is reacted with a custom-designed molecule that contains a boron group at one end as the boron linkage forms a reversible bond to the sugar. The other end of this custom molecule is made to react with molecules that have been tethered to a gold surface. The glycoprotein is then bound to the surface via its sugar groups, before the rest of the surface is blocked with a third molecule. When the glycoprotein is removed by breaking the reversible boron bonds it leaves behind a perfect cast. Within that cast, there was a special area with boron-containing molecules that can recognize a specific set of sugars. Surface plasmon resonance (SPR) analyses were performed at 25 °C with the Dual Channel SPR Spectrometer (Reichert, Buffalo, NY, USA).

John S. Fossey, PhD, a senior lecturer and a coauthor of the study, said, “It's estimated that one in eight men will suffer from prostate cancer at some point in their life, so there's a clear need for more accurate diagnosis. By focusing on the sugar, we appear to have hit the ‘sweet spot’ for doing just that. Our focus now is to take this technology and develop it into something accessible to people across the world. We believe that this could be applicable to other diagnostic challenges. Lots of diseases produce specific glycoproteins, so there are a number of possible avenues to improve the accuracy of our diagnoses.” The study was published on June 17, 2015, in the journal Chemical Science.

Related Links:

University of Birmingham
Reichert



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
New
Automated Immunoassay Analyzer
SuperFlex™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image Credit: Adobe Stock

Mayo Clinic and Thermo Fisher Launch Multi-Omics Venture to Identify Early Disease Signals

Many diseases begin developing years before symptoms emerge, making early detection difficult for healthcare systems and clinical laboratories. Linking molecular changes with longitudinal health data could... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.